A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
暂无分享,去创建一个
S. Agelaki | V. Georgoulias | K. Syrigos | I. Varthalitis | A. Pallis | A. Kotsakis | N. Kentepozidis | G. Pavlakou | E. Kontopodis | A. Agelidou